Caroline M Albrecht1, Nancy K Sweitzer2, Maryl R Johnson2, Orly Vardeny3. 1. School of Pharmacy, University of Wisconsin, Madison, Wisconsin. 2. School of Medicine and Public Health, University of Wisconsin, Madison, Wisconsin. 3. School of Pharmacy, University of Wisconsin, Madison, Wisconsin. Electronic address: ovardeny@pharmacy.wisc.edu.
Abstract
BACKGROUND: Patients with heart failure (HF) have lower initial antibody responses to the influenza vaccine compared with healthy individuals. Whether antibody titers wane faster in this population remains unknown. METHODS AND RESULTS: We studied 62 HF patients (18 ischemic, 44 idiopathic) and 40 healthy control subjects (HC) during the 2006-2007 and 2007-2008 influenza seasons. Antibody titers were measured before and 2-4 weeks and 11-12 months after vaccination. Serum antibody production was measured by hemagglutination inhibition assay, and antibody titers to individual vaccine viral strains between the HF and HC groups were compared after the influenza season to measure persistence of antibody response. All participants demonstrated early antibody seroprotection (titers 40 hemmaglutination inhibition units to 1 strain). Although antibody titers waned over time in both groups, titers to A/H3N2 and A/H1N1 strains decreased more in HF than in HC participants (P = .004 and P = .04, respectively). Titers to the B-type strain decreased to below seroprotective levels in both groups. CONCLUSIONS: Antibody titers to influenza A vaccine strains wane to below seroprotective levels in HF patients compared with HC, despite similar rates of initial seroprotection and seroconversion. These findings suggest that HF patients may remain at increased risk for influenza infection despite annual vaccination.
BACKGROUND:Patients with heart failure (HF) have lower initial antibody responses to the influenza vaccine compared with healthy individuals. Whether antibody titers wane faster in this population remains unknown. METHODS AND RESULTS: We studied 62 HF patients (18 ischemic, 44 idiopathic) and 40 healthy control subjects (HC) during the 2006-2007 and 2007-2008 influenza seasons. Antibody titers were measured before and 2-4 weeks and 11-12 months after vaccination. Serum antibody production was measured by hemagglutination inhibition assay, and antibody titers to individual vaccine viral strains between the HF and HC groups were compared after the influenza season to measure persistence of antibody response. All participants demonstrated early antibody seroprotection (titers 40 hemmaglutination inhibition units to 1 strain). Although antibody titers waned over time in both groups, titers to A/H3N2 and A/H1N1 strains decreased more in HF than in HC participants (P = .004 and P = .04, respectively). Titers to the B-type strain decreased to below seroprotective levels in both groups. CONCLUSIONS: Antibody titers to influenza A vaccine strains wane to below seroprotective levels in HF patients compared with HC, despite similar rates of initial seroprotection and seroconversion. These findings suggest that HF patients may remain at increased risk for influenza infection despite annual vaccination.
Authors: Amy Van Ermen; Matthew P Hermanson; John M Moran; Nancy K Sweitzer; Maryl R Johnson; Orly Vardeny Journal: Eur J Heart Fail Date: 2013-01-04 Impact factor: 15.534
Authors: J K Kiecolt-Glaser; R Glaser; S Gravenstein; W B Malarkey; J Sheridan Journal: Proc Natl Acad Sci U S A Date: 1996-04-02 Impact factor: 11.205
Authors: Florence H Y Yap; Pak-Leung Ho; Kwok-Fai Lam; Paul K S Chan; Yeung-Hung Cheng; Joseph S M Peiris Journal: J Med Virol Date: 2004-08 Impact factor: 2.327
Authors: Janet E McElhaney; John M Herre; M Louise Lawson; Sharon K Cole; Bonnie L Burke; Jonathan W Hooton Journal: Vaccine Date: 2004-01-26 Impact factor: 3.641
Authors: Chris P Verschoor; Alina Lelic; Robin Parsons; Carole Evelegh; Jonathan L Bramson; Jennie Johnstone; Mark B Loeb; Dawn M E Bowdish Journal: J Infect Dis Date: 2017-07-15 Impact factor: 5.226
Authors: David M Leone; Hong-Jai Park; Serhan Unlu; Michelle Gurvitz; Insoo Kang; Robert W Elder Journal: Int J Cardiol Congenit Heart Dis Date: 2022-03-25
Authors: Bahar Behrouzi; Maria Viviana Araujo Campoverde; Kyle Liang; H Keipp Talbot; Isaac I Bogoch; Allison McGeer; Ole Fröbert; Mark Loeb; Orly Vardeny; Scott D Solomon; Jacob A Udell Journal: J Am Coll Cardiol Date: 2020-10-13 Impact factor: 24.094
Authors: Amanda H W Chong; Ruth E Mitchell; Gibran Hemani; George Davey Smith; Robert H Yolken; Rebecca C Richmond; Lavinia Paternoster Journal: Front Immunol Date: 2021-11-04 Impact factor: 7.561